Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 3Recruiting 3Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Breast Neoplasms 849Carcinoma, Non-Small-Cell Lung 551Neoplasms 509Prostatic Neoplasms 501Lung Neoplasms 313Colorectal Neoplasms 307Multiple Myeloma 289Neoplasm Metastasis 251Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 209Pancreatic Neoplasms 206Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 164Stomach Neoplasms 162Recurrence 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 151Glioblastoma 147Uterine Cervical Neoplasms 144Head and Neck Neoplasms 141Lymphoma, Non-Hodgkin 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 114Lymphoma, Follicular 112

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Metastatic Breast Cancer × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Criterium, Inc.

Phase 1/2 Active not recruiting
40 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡